Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance  by Bauer, Bettina E et al.
Review
Inventory and function of yeast ABC proteins: about sex, stress,
pleiotropic drug and heavy metal resistance
Bettina E. Bauer, Hubert Wolfger, Karl Kuchler *
Department of Molecular Genetics, University and Bio Center of Vienna, Dr. Bohr-Gasse 9/2, A-1030 Vienna, Austria
Received 31 August 1999; accepted 1 September 1999
Abstract
Saccharomyces cerevisiae was the first eukaryotic organism whose complete genome sequence has been determined,
uncovering the existence of numerous genes encoding proteins of the ATP-binding cassette (ABC) family. Fungal ABC
proteins are implicated in a variety of cellular functions, ranging from clinical drug resistance development, pheromone
secretion, mitochondrial function, peroxisome biogenesis, translation elongation, stress response to cellular detoxification.
Moreover, some yeast ABC proteins are orthologues of human disease genes, which makes yeast an excellent model system
to study the molecular mechanisms of ABC protein-mediated disease. This review provides a comprehensive discussion and
update on the function and transcriptional regulation of all known ABC genes from yeasts, including those discovered in
fungal pathogens. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The ATP-binding cassette (ABC) protein family
with currently more than 1000 members represents
the largest protein family known to date [1]. These
proteins operate in all living cells from bacteria to
man [1,2] and ful¢ll a remarkable variety of cellular
functions. While most ABC proteins are purely ATP-
driven membrane translocators, some of them act as
ion channels, channel regulators, receptors, pro-
teases, and even sensing proteins [3]. As for the
transport substrates, ABC transporters mediate
membrane translocation of ions, heavy metals, car-
bohydrates, anticancer drugs, amino acids, phospho-
lipids, steroids, glucocorticoids, bile acids, myco-
toxins, antibiotics, pigments, peptides and even
whole proteins [1,4^6]. However, the mechanism by
which transport of such a substrate variety and
size diversity can be achieved, while each ABC trans-
porter maintains selectivity for its particular sub-
strate, represents an intriguing and yet unsolved mys-
tery.
All ABC proteins share a similar molecular archi-
tecture with a hallmark domain organization that
includes the presence of at least one evolutionarily
conserved ABC, also known as NBD (for nucleotide
binding domain), as well as several predicted K-heli-
cal membrane-spanning segments (TMS). The TMSs
and NBDs are normally arranged in a duplicated
forward (TMS6-NBD)2 or reverse (NBD-TMS6)2
con¢guration, but numerous half-size transporters
with various topologies are also known [1,5,7].
Full-size ABC proteins usually have six predicted
TMSs in each half, connected by a charged linker
region. Additional TMSs proximal to the N-terminus
also exist in some ABC proteins [8]. Finally, the hy-
drophilic NBDs encompass approximately 250 resi-
dues with ¢ve conserved protein motifs. The Walker
A and Walker B motifs, also found in all other nu-
cleotide binding proteins [9], and the ABC signature
or C motif with the consensus sequence LSGGQ, are
diagnostic hallmarks for all ABC proteins. In addi-
tion, there are two less conserved regions, the so-
called center region between Walker A and Walker
B and another one downstream of the Walker B
motif [2].
Several mammalian ABC proteins are medically
important, because mutations in the corresponding
genes cause severe genetic diseases such as cystic ¢-
brosis [10,11], adrenoleukodystrophy [12] and Zell-
weger syndrome [13,14], familial hyperinsulinemic
hypoglycemia of infancy [15], Dubin-Johnson syn-
drome [16^18], hepatic cholestasis [19,20] and Star-
gardt’s macular dystrophy [21]. Antigen presentation
via class I MHC requires the action of dedicated
peptide transporters of the ABC family [22]. Further-
more, overexpression of certain mammalian P-glyco-
proteins (P-gp) [23] and multidrug resistance-associ-
ated proteins (MRP) [8] renders both tumor and
cultured cells highly resistant to many di¡erent che-
motherapeutic drugs. The characteristics of the
MDR phenomenon include an initial resistance to
a single anticancer drug to which tumor cells are
exposed, followed by the development of cross-resist-
ance to many structurally and functionally unrelated
drugs [24]. The same mechanism of multiple drug
resistance development exists in pathogenic fungi
such as Candida and Aspergillus [25], in parasites
such as Plasmodium and Leishmania [26,27], as well
as in many infectious bacteria [28].
The baker’s yeast Saccharomyces cerevisiae is the
¢rst eukaryotic organism whose complete genome
sequence has been determined, revealing the presence
of numerous ABC genes [29,30]. Importantly, mam-
malian MDR is analogous to pleiotropic drug resis-
tance (PDR) in yeast, which involves a highly com-
plex network of transcriptional regulators that
control expression of membrane ABC drug e¥ux
pumps [31,32]. Moreover, yeast has several ortho-
logues of mammalian disease genes, which makes
yeast an invaluable model system for unraveling the
molecular mechanisms of ABC protein function to
better understand and treat ABC gene-mediated dis-
eases. This review is devoted to a comprehensive dis-
cussion of yeast ABC proteins identi¢ed in pathogen-
ic and non-pathogenic fungi.
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2. The inventory of ABC proteins in S. cerevisiae
The genome sequencing project revealed the exis-
tence of 31 distinct ABC genes in this lower eukar-
yote [29,30,33]. Notably, each cellular compartment,
except for the endoplasmic reticulum (ER) and nu-
clear membrane, appears to harbor at least one ABC
transporter. Some membranes like the plasma mem-
brane carry several di¡erent ABC transporters at any
given moment (Fig. 1). Based on phylogenetic tree
analysis, a classi¢cation of yeast ABC proteins into
six distinct subfamilies has been suggested [33]. These
families are de¢ned as the MDR, the PDR, the
MRP/CFTR, the ALDp, the YEF3 and the RLI
subfamilies (Table 1).
2.1. The MDR subfamily ^ sex life and mitochondrial
function
The MDR subfamily comprises four members, one
of which is the Ste6p a-factor pheromone transport-
er, probably one of the best characterized yeast ABC
transporters. The STE6 gene was cloned some 10
years ago as a homologue of the mammalian P-gp
[34,35]. Ste6p is a very short-lived [36], haploid-spe-
ci¢c membrane transporter mediating MATa cell-
speci¢c export of the farnesylated a-factor sex pher-
omone whose precursor lacks a typical hydrophobic
signal peptide [37,38]. Extracellular a-factor is essen-
tial for the sexual reproduction cycle of haploid yeast
cells. Pheromone export occurs through a non-clas-
sical route, bypassing the vesicular secretory pathway
[37,38]. While the steady-state localization of Ste6p
appears to be in the Golgi complex and/or the endo-
somes [36,39,40], Ste6p functions at the plasma mem-
brane providing the rate-limiting step in a-factor ex-
port [34,39]. After pheromone extrusion, Ste6p is
rapidly endocytosed and delivered to the vacuole
for terminal degradation [36,40]. In addition to
STE6, several other genes are required for the pro-
duction of a-factor [37,38]. These genes include those
involved in the post-translational modi¢cations and
maturation of the pheromone precursor at the C-ter-
minal CAAX box, as well as several proteases which
are required to obtain a fully processed and biolog-
ically active sex pheromone [37,38].
Interestingly, severing experiments have shown
that the two Ste6p halves, when coexpressed as in-
dividual proteins, can mediate pheromone export.
This demonstrates that both Ste6p halves are re-
quired for function and that they can interact in
vivo to form a functional a-factor transporter [38].
The substrate, a-factor, is extremely hydrophobic due
to its C-terminal lipid modi¢cation and carboxy-
methylation. While mutations in the structural gene
encoding a-factor do not dramatically a¡ect its secre-
tion, a lack of a-factor farnesylation or methylation
debilitates its extrusion. Hence, the lipid moiety or its
hydrophobicity may represent an essential recogni-
tion determinant for Ste6p. As with many other eu-
karyotic ABC transporters, Ste6p is fueled by ATP
hydrolysis, because many NBD mutations destroy
function [41], and because Ste6p binds photo-acti-
vateable ATP analogues [39]. Interestingly, Ste6p
might also play an additional role in cell fusion, since
ste6 mutants were isolated that still mediate a-factor
export, but fail to complete fusion of haploid mating
partners [42]. Taken together, the precise mechanism
by which Ste6p mediates the actual pheromone
translocation across the plasma membrane is some-
what mysterious, but it appears as if intracellular a-
factor precursor processing and translocation across
the plasma membrane are tightly coupled.
The second member of the MDR family is the
Atm1p half-size transporter [43], the only known mi-
tochondrial ABC transporter in yeast. Atm1p is lo-
Fig. 1. Subcellular localization of S. cerevisiae ABC transport-
ers. ER, endoplasmic reticulum; G, Golgi apparatus; M, mito-
chondrion; N, nucleus; P, peroxisomes; and V, vacuole. Ste6p
is localized in Golgi vesicles, endosomes as well as in the plas-
ma membrane.
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Table 1
S. cerevisiae ABC proteins
ABC protein Substrate(s) Length Topology Localization Phenotype Reference
MDR family
Ste6p a-factor 1290 (TMS6-ABC)2 PM, GV, ES Sterile [34,35]
Atm1p Fe/S proteins 694 TMS6-ABC Mit Slow-growth [43]
Ssh1p/Mdl2p ? 820 TMS6-ABC ? Viable [7,49]
Mdl1p ? 696 TMS6-ABC ? Viable [49]
PDR family
Pdr5/Sts1/Ydr1/
Lem1p
Drugs, steroids,
antifungals
1511 (ABC-TMS6)2 PM DrugHS [60^63]
Pdr10p ? 1564 (ABC-TMS6)2 PM Viable [77,178]
Pdr15p ? 1529 (ABC-TMS6)2 PM Viable [77,178]
Snq2p Drugs, steroids,
mutagens
1501 (ABC-TMS6)2 PM DrugHS [59]
Pdr12p Weak acids 1511 (ABC-TMS6)2 PM Weak acidHS [78]
Pdr11p ? 1411 (ABC-TMS6)2 PM(?) Viable [72]
Adp1p ? 1049 TMS2-ABC-TMS7 ? Viable [81]
YNR070w ? 1333 (ABC-TMS6)2 ? ? Z71685
YOR011w ? 1394 (ABC-TMS6)2 ? ? Z74919
YOL075c ? 1095 (ABC-TMS6)2 ? ? Z74817
MRP/CFTR family
Yor1p Oligomycin,
reveromycin
1477 (TMS6-ABC)2 PM DrugHS [97]
Ycf1p GS-conj./Cd2 1515 (TMS6-R-ABC)2 Vac CdHS [87]
Bat1p Bile acids 1661 (TMS6-ABC)2 Vac Viable [85]
YLL015w ? 1559 (TMS6-ABC)2 ? ? Z73120
YHL035c ? 1592 (TMS6-ABC)2 ? ? U11583
YKR103w ? 1218 TMS6-ABC-TMS6 ? ? Z28328
YKR104w ? 306 ABC ? ? Z28329
ALDp family
Ssh2/Pal1/Pxa1/Pat2p Long-chain fatty acids 870 TMS6-ABC Px Oleate3 [7,101,102,205]
YKL741/Pxa2/Pat1p Long-chain fatty acids 853 TMS6-ABC Px Oleate3 [100,101,206]
YEF3 family
Yef3p Drugs 1044 ABC2 Ribo?, Cyto? Essential [111]
Gcn20p ? 752 ABC2 Ps Viable [112]
YNL014w/Hef3p ? 1044 ABC2 Cyto? Viable [116,117]
YPL226w ? 1196 ABC2 ? ? Z73582
YER036c ? 610 ABC2 ? ? U18796
RLI family
YDR091c ? 608 ABC2 ? ? Z50111
Others
YDR061w ? 539 ABC ? ? Z49209
YFL028c ? 289 ABC ? ? D50617
Where no published references are available, the EMBL/GenBank sequence accession or the NCBI identi¢cation numbers are listed to
allow for sequence retrieval. conj., conjugates; Cyto, cytoplasm; ES, endosome; GS, glutathione; GV, Golgi vesicle ; HS, hypersensi-
tivity; Mit, mitochondria; PM, plasma membrane; Ps, polysomes; Px, peroxisome; R, regulatory domain; Ribo, ribosome; TMS,
transmembrane segment; Vac, vacuole.
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calized in the inner mitochondrial membrane with
the NBD facing the matrix [43]. An uncleaved target-
ing signal at the N-terminus of Atm1p, when fused
to the N-terminus of otherwise cytoplasmic proteins,
can properly target these proteins to the mitochon-
dria. A vatm1 deletion strain is unable to grow on
non-fermentable carbon sources, lacks all major mi-
tochondrial cytochromes and becomes rho3 upon
prolonged propagation [43]. Moreover, vatm1 strains
accumulate high levels of free iron, indicating a role
for Atm1p in mitochondrial iron homeostasis [44].
Strikingly, a very recent study provides direct evi-
dence that Atm1p is required for the export of Fe/
S-containing proteins from the mitochondrial matrix
[45]. Such a function of Atm1p seems plausible, since
a close Atm1p homologue in humans, hABC7, has
been linked to a heritable disease known as X-linked
sideroblastic anemia with spinocerebellar ataxia [46^
48].
Finally, two MDR family members of unknown
function and subcellular localization were identi¢ed
by PCR-based cloning using degenerate oligonucleo-
tides. Both Mdl1p [49] and Mdl2p/Ssh1p [7,49] are
typical half-size transporters. It is not known
whether they form homo- or heterodimers or if
they are functionally related at all. Deletion of either
one or both genes does not result in obvious growth
phenotypes [49].
Ste6p was the ¢rst yeast ABC transporter, closing
a gap between the Escherichia coli hlyB hemolysin A
export system [6] and the human P-glycoproteins me-
diating multidrug resistance [50]. Notably, functional
expression of certain mammalian P-gps in yeast can
partially complement loss of Ste6p, suggesting that
P-gps are able to transport peptide substrates of var-
ious length [7,51]. Several other studies also demon-
strated P-gp-mediated peptide transport [52^56]. On
the other hand, Ste6p overexpression does not lead
to a signi¢cant multidrug resistance phenotype,
although some low resistance to the peptide iono-
phore valinomycin has been reported [34]. At any
rate, the existence of inherent multidrug resistance
phenotypes in yeast has prompted many laboratories
to search for functional homologues of P-gps. These
concerted e¡orts were rewarded by the discovery of
PDR genes, which represent the second subfamily of
yeast ABC transporters.
2.2. The PDR subfamily ^ pleiotropic drug resistance
and cellular detoxi¢cation
The largest ABC subfamily in yeast has 10 mem-
bers, all of which have a ‘reverse’ topological orien-
tation, with the TMS following the NBD. Except for
Adp1p, all PDR genes are full-size transporters with
usually 12 predicted TMSs. Several PDR members
share high homology with the white, brown, and scar-
let transporters from Drosophila melanogaster and
human ABC8 [57,58]. The best characterized PDR
members, and by now perhaps the best characterized
yeast ABC transporters overall, include the PDR5/
STS1/YDR1/LEM1 and SNQ2 genes, both of which
are functional homologues of mammalian P-gps, as
their overexpression confers PDR in yeast [31,32].
Snq2p was the ¢rst identi¢ed PDR transporter
conferring multidrug resistance, particularly resis-
tance to mutagens such as 4-nitroquinoline-N-oxide
(4-NQO) and methyl-nitro-nitrosoguanidine
(MNNG) [59]. Shortly after the discovery of
Snq2p, Pdr5p was independently identi¢ed by four
di¡erent laboratories using various genetic ap-
proaches. PDR5 was cloned as a cycloheximide re-
sistance gene [60], as a gene mediating resistance to
mycotoxins such as sporidesmin [61], and cross-re-
sistance to cerulenin and cycloheximide [62], and,
¢nally, as a selective transporter of glucocorticoids
[63]. Although cells lacking Pdr5p and Snq2p are
viable, they are hypersensitive to a vast number of
xenobiotics, particularly antifungals and anticancer
drugs [31,64]. In the mean time, Pdr5p and Snq2p
were shown to transport hundreds (!) of structurally
and functionally unrelated drugs with a considerable
overlap in substrate speci¢city [59,64^67]. Notably,
Snq2p also modulates resistance to metal ions such
as Na, Li, and Mn2 [68]. A vsnq2vpdr5 double
deletion strain exhibits a more pronounced e¡ect re-
garding intracellular metal ion accumulation and
metal sensitivity, implying some functional overlap
between Snq2p and Pdr5p. However, the formal pos-
sibility remains that expression of Pdr5p, Snq2p or
both somehow modulates plasma membrane perme-
ability rather than mediating active transport of met-
al ions.
The Pdr5p and Snq2p pumps are plasma mem-
brane proteins [69^72], which undergo endocytosis
and vacuolar delivery for terminal degradation
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[69,70]. The cell surface localization of Pdr5p and
Snq2p was also con¢rmed in living cells using func-
tional Snq2p-GFP (Kuchler et al., unpublished) and
Pdr5p-GFP variants [65]. Hence, ATP-dependent
drug e¥ux is the most likely mechanism by which
Pdr5p/Snq2p mediate PDR. This was con¢rmed for
Pdr5p in vivo using rhodamine 6G accumulation and
e¥ux assays in the presence and absence of inhibitors
such as vanadate, vinblastine or the immunosuppres-
sive agent FK506 [65,73]. Pdr5p and mammalian P-
gps are therefore true functional homologues because
they share several substrates, are inhibited by the
same compounds, and because drug transport re-
quires ATP hydrolysis. Like P-gp, Pdr5p can be pho-
toa⁄nity labeled by a photo-activateable ATP ana-
logue [74]. The NTPase activity of Pdr5p is not
limited to ATP, as Pdr5p also hydrolyzes UTP and
CTP and to a lower extent ITP and GTP, whereas
the Snq2p ATPase seems restricted to ATP hydrol-
ysis [72].
A detailed mutational analysis of Pdr5p enabled
the identi¢cation of residues important for function,
drug substrate speci¢city and inhibitor susceptibility
[65]. Non-functional Pdr5p mutants can arise from
misfolding in the ER membrane [75]. Notably, the
C1427Y mutation in a predicted extracellular (lume-
nal) loop of Pdr5p causes its e⁄cient retention in the
ER membrane, followed by rapid polyubiquitin
modi¢cation and degradation by the cytoplasmic
proteasome [75]. The instability of C1427Y-Pdr5p
is caused by a lack of disul¢de bond formation in
the ER lumen, which is a prerequisite for native
Pdr5p folding and exit from the ER (Egner et al.,
in preparation). In contrast, a human P-gp lacking
all cysteines is still functional in drug transport and is
normally transported to the cell surface [76].
The random in vitro mutagenesis approach also
allowed the isolation of several mutant Pdr5p pumps
with altered substrate speci¢city [65]. The most inter-
esting Pdr5p mutant has a S1360F exchange in the
predicted K-helical TMS10. This mutation causes a
restricted substrate speci¢city for the antifungal ke-
toconazole, with poor resistance to itraconazole and
cycloheximide. Most remarkably, the inhibition of
ketoconazole resistance by the immunosuppressive
FK506 is completely absent in Pdr5p-S1360F, where-
as wild type Pdr5p is unable to confer resistance to
ketoconazole in the presence of FK506 [65]. The
S1360F exchange is located on the hydrophilic side
in the center of TMS10. Hence, this mutant allowed
the genetic separation of drug substrate speci¢city
and inhibitor susceptibility of Pdr5p. The S1360F
exchange is most likely to cause a disturbance of
general helix packing in Pdr5p due to the introduc-
tion of a large hydrophobic residue, thereby modu-
lating drug speci¢city. Further mutational analysis of
the Pdr5p TMS10 revealed that this helix is a pri-
mary determinant for substrate speci¢city, inhibitor
susceptibility as well as the overall folding of Pdr5p
(Egner et al., submitted).
The Pdr5p drug e¥ux pump has two additional
homologues, Pdr10p and Pdr15p, which share more
than 65% overall sequence identity with Pdr5p.
PDR10 and PDR15 were identi¢ed earlier by South-
ern hybridization using a PDR5-speci¢c probe [61]
and later during the yeast genome sequencing [77].
Although the functions of Pdr10p and Pdr15p are
unknown at present, both are localized at the cell
surface (Wolfger et al., unpublished). Vegetative cells
express very low amounts of both proteins, but their
high expression under various stresses suggests that
both genes might represent novel stress response
genes (see Section 5.1).
The closest homologue of Snq2p is Pdr12p, shar-
ing about 60% primary sequence identity. However,
in contrast to Snq2p, expression of Pdr12p mediates
pronounced resistance to weak organic acids such as
sorbate, benzoate and propionate, compounds that
are frequently used as food preservatives [78]. Thus,
Pdr12p overexpression confers resistance to water-
soluble carboxylate anions rather than to hydropho-
bic drugs [78]. The most recently identi¢ed substrates
of Pdr12p are £uorescein-like compounds [79]. More-
over, acetate, which is produced through the normal
metabolism, is also a Pdr12p substrate [78]. Expres-
sion of Pdr12p is dramatically induced under weak
acid stress and low pH, although other stresses such
as high osmolarity or ethanol also induce Pdr12p,
albeit to a much lesser extent [78]. Pdr12p is also
required for adaptation of cells to growth in the
presence of metabolic stress. Consistent with these
¢ndings, vpdr12 cells are highly sensitive to weak
organic acids. Pdr12p-mediated weak acid resistance
and its induction, however, are independent of tran-
scriptional regulators normally involved in stress re-
sponse, including Yap1p and Msn2p/Msn4p [80].
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Furthermore, PDR12 expression under stress is not
in£uenced by the Pdr1p/Pdr3p master regulators of
the PDR network, indicating that novel and as yet
unidenti¢ed transcription factors control expression
of certain PDR genes under normal and in response
to adverse conditions [78].
The PDR family has additional homologues of
Snq2p and Pdr12p, namely Pdr11p, YOR011w, and
YNR070w, none of which has been studied so far
and thus nothing is known about their function,
drug substrates or regulation of expression. Pdr11p
might be localized to the plasma membrane, since
peptide sequencing of a 170 kDa protein from parti-
ally puri¢ed plasma membrane fractions also yielded
Pdr11p-speci¢c peptides [72]. Finally, although
Adp1p was one of the ¢rst known PDR members
originally discovered through yeast chromosome III
sequencing [81], literally nothing is known as yet
about the physiological function of Adp1p. Adp1p
is closely related to YOL075c, another PDR member
of unknown function. Notably, Adp1p has some in-
teresting structural features such as only one central
NBD linked to two and seven predicted TMSs at the
N- and C-terminus, respectively, and the presence of
EGF repeats in predicted extracellular domains. The
non-essential Adp1p shows homology to human
ABC8 [58,82] and white, brown and scarlet [57], £y
ABC transporters presumably involved in pteridine
pigment transport in the eye [83]. Interestingly, there
is evidence for a placental-speci¢c mammalian homo-
logue of Adp1p, but its function is also unknown
[84].
2.3. The MRP subfamily ^ vacuolar detoxi¢cation
and heavy metal resistance
This subfamily harbors six ORFs that show signif-
icant homology to mammalian MRP and to a lesser
extent to CFTR. At least two genes of this family,
YCF1 and YOR1, have been studied so far. A recent
investigation characterized another related transport-
er, Bat1p, a bile acid transporter located in the yeast
vacuolar membrane [85]. Bat1p mediates vacuolar
uptake of bile acids such as taurocholate, suggesting
that a vbat1 deletion mutant might be a valuable
host to analyze mammalian bile acid transporters
associated with hepatic cholestasis [19]. The normal
function of Bat1p is not well understood, but it
might be responsible for vacuolar sequestration of
heme-derived catabolites, which could be considered
bile-like molecules in yeast.
The ¢rst evidence for active transporters in inter-
nal membranes was the discovery of a saturable,
MgATP- and temperature-dependent transport of
taurocholate and S-(2,4-dinitrophenyl)-glutathione
(DNP-GS) into secretory vesicles isolated from a
sec1 strain [86]. Inhibition experiments implied that
at least two dedicated ABC transporters could be
involved [86]. Indeed, the ¢rst ABC transporter was
identi¢ed in Ycf1p, a 1515-residue homologue of
mammalian MRP [8]. There is also a weak homology
to the human cystic ¢brosis transmembrane conduc-
tance regulator [87], since Ycf1p has a rudimentary
R-domain only present in CFTR [88]. Ycf1p over-
expression allows yeast cells to grow in the presence
of increased cadmium concentrations [87]. Moreover,
both in vitro and in vivo experiments demonstrated
that Ycf1p is a vacuolar glutathione S-conjugate
pump [89]. In addition to Cd2, Ycf1p mediates vac-
uolar transport of oxidized glutathione (glutathione
disul¢de, GSSG), DNP-GS, and several other gluta-
thione S-conjugates through an MgATP-dependent
mechanism [89^91]. Another recently identi¢ed role
of Ycf1p is to mediate resistance to arsenite, arsenate
and antimony, because uptake of As(GS)3 into vac-
uoles is completely abolished in vycf1 cells [92].
These metalloids are removed from the cytosol after
their conjugation to GSH through Ycf1p-mediated
transport into the vacuole. Taken together, Ycf1p
appears to be a key player for the vacuolar detoxi¢-
cation via GSH conjugates. Interestingly, Ycf1p ex-
pression is regulated by stress response factors such
as Yap1p [93], since yap1 mutants exhibit cadmium
hypersensitivity [94]. However, YAP1 overexpression
mediates Cd2 resistance only in the presence of
functional Ycf1p, whereas hyperresistance to Cd2
through overexpressed Ycf1p was only partly de-
pendent on the presence of functional Yap1p [94]
(see also Section 5.2).
Mutational analysis of YCF1 investigated the phe-
notypes of mutations that were constructed by anal-
ogy to the most prominent mutations found in hu-
man CFTR. The vF713 mutation in YCF1 is the
functional analogue of the vF508 deletion in human
CFTR, the most frequent mutation in cystic ¢brosis
(CF) patients. This mutation leads to a Ycf1p mis-
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localization to the ER membrane and loss of Cd2
resistance [95]. Furthermore, wild type Ycf1p mi-
grates as two distinct bands of approximately 120
kDa and 170 kDa when overexpressed, while the
mutant vF713-Ycf1p appears only as a 120 kDa
protein. Pulse-chase experiments showed that the
170 kDa band disappeared upon extended chase
times, whereas the 120 kDa band is the only one
comigrating with vacuolar marker proteins in frac-
tionation experiments. Notably, both Ycf1p forms
are functional. The 170 kDa might represent a func-
tional Ycf1p precursor of the mature 120 kDa Ycf1p
[95]. Hence, glycosylation is likely to play an impor-
tant role in the tra⁄cking and/or folding of Ycf1p
[95] in the ER membrane, similar to the situation
observed for Pdr5p [65].
The second well-characterized yeast MRP homo-
logue is the YOR1/YRS1 gene product Yor1p, an-
other ABC protein of the plasma membrane [96].
Genetic screens for oligomycin and reveromycin A
resistance lead to the independent cloning of YOR1
[97] and YRS1 [98]. A vyor1 deletion mutant is via-
ble, but hypersensitive to the respective drugs, as well
as several other xenobiotics [97^99]. Like Pdr5p and
Snq2p, Yor1p-dependent drug resistance is mediated
by e¥ux across the plasma membrane, as shown by
rhodamine B accumulation experiments [74,98]. In
vyor1 cells, a four-fold higher £uorescence was meas-
ured than in wild type cells. Furthermore, this e¥ux
requires ATP hydrolysis but is H-ATPase-inde-
pendent. Again, vanadate inhibits Yor1p-mediated
drug transport [74].
Mutations were also introduced into YOR1 based
on prominent CFTR mutations. Although Ycf1p
and Yor1p have a di¡erent cellular localization, the
results from the mutational analysis were quite sim-
ilar. The mutant vF670-Yor1p, the equivalent of the
CFTR vF508, was also retained in the ER and failed
to confer oligomycin resistance. Pulse-chase experi-
ments using mutants defective in the secretory path-
way and vacuolar degradation led to the following
Yor1p degradation model [96]: Yor1p must exit the
ER for proteolytic turnover, which most likely is
independent of ubiquitination and takes place in
the vacuole. However, the misfolded vF670-Yor1p
mutant is degraded in the ER, although some con-
tribution of vacuolar proteases cannot be ruled out.
Ubiquitination stimulates the breakdown of the
vF670-Yor1p mutant by the proteasome. Additional
Yor1p mutants have been characterized, all of which
are expressed at more or less wild type levels, but
display reduced oligomycin resistance. While some
of these mutations cause ER retention (e.g. insertion
of an A at position 652), others (K715M, K715Q)
are still normally delivered to the cell surface. Nota-
bly, the analogous mutation to K715M and K715Q
in CFTR and Ycf1p resulted in hyperactive gain-of-
function alleles [96].
Finally, the YKR103w and YKR104w ORFs were
originally believed to represent two distinct genes
separated by a single stop codon. However, these
ORFs perhaps encode a non-essential full-size trans-
porter, as the stop codon resulted from a sequencing
error [33]. Likewise, the functions of the YHL035c,
YLL015w genes have not been elucidated. Based on
their homology to Ycf1p and Bat1p, however, it is
tempting to speculate that they might have at least
partially overlapping functions.
2.4. The yeast ALDp subfamily and human genetic
diseases
This is a small subfamily of yeast ABC transport-
ers with two peroxisomal membrane proteins, Pxa1p/
Pat2p/Pal1p/Ssh2p and Pxa2p/Pat1p/Pal2p [7,100^
102]. The half-size ABC protein Pxa1p is the closest
homologue of the human peroxisomal ABC trans-
porters Pmp70 [13,14,103] and ALDp [12] implicated
in Zellweger syndrome and X-linked adrenoleuko-
dystrophy (ALD), respectively. Both diseases are as-
sociated with apparent defects in peroxisome func-
tion and/or organelle assembly. Moreover, a
demyelination of the nervous system, paralleled by
the accumulation of very-long-chain fatty acids
(VLCFA) in peroxisomes [14,104] is observed.
Although these neurodegenerative diseases have
sometimes di¡erent clinical phenotypes, most are
characterized by a lack of mature peroxisomes and
activities of peroxisomal enzymes [13,105,106].
Like their human counterparts, Pxa1p and Pxa2p
are both half-size transporters of the peroxisomal
membrane [100,102]. Since single deletions of each
gene had the same e¡ect as deletion of both genes,
namely an inability to grow on oleic acid as the sole
carbon source and a failure in L-oxidation, they are
thought to heterodimerize to a functional transporter
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[100,102]. The Pxa1p/Pxa2p transporter could medi-
ate uptake of activated LCFA from the cytosol into
the yeast peroxisomal matrix, were they are subjected
to the L-oxidation machinery [100,101,107].
Both PXA1 and PXA2 are regulated by the tran-
scription factors Oaf1p and Pip2p, which play a key
role in activating genes in the presence of fatty acids
such as oleate [108]. For PXA2 this regulation was
not unexpected, since its promoter contains an oleate
response element (ORE). However, PXA1 expression
was also induced by oleate in an Oaf1p/Pip2p-de-
pendent manner, despite an apparent lack of obvious
OREs in its promoter region [108]. Thus, additional
as yet unknown regulators might control peroxiso-
mal function and proliferation in yeast.
Sequence comparisons of Pxa1p/Pxa2p with
ALDp and PMP70 revealed two highly conserved
motifs among Pxa1p and PMP70, ALDp and several
P-gps [109]. Both motifs, designated loop1 between
TMS4 and TMS5, and the EAA-like motif immedi-
ately distal of TMS1, are clearly important for Pxa1p
function [109]. Discrete mutations in both regions of
PXA1 lead to a loss-of-function phenotype, although
Pxa1p is still normally expressed and targeted to the
peroxisome. Interestingly, mutations in the corre-
sponding regions of ALDp have been linked to
ALD, suggesting that the EAA-like motif and the
loop1 motif are crucial for function throughout the
ALDp subfamily and its human orthologues. In hu-
man cells, two additional half-size transporters with
high homology to ALDp and PMP70 have been
identi¢ed recently [105,106,110]. The suggestion
arises that functional transporters could heterodimer-
ize from di¡erent sets of half-size transporters to
provide distinct functions in di¡erent tissues. This
could explain the clinical di¡erences of various
ALD forms, as being the consequence of di¡erent
ALD transporters [110]. The precise functions or
substrates of PMP70 and ALDp have not been com-
pletely worked out, although it has been suggested
that they may operate as transporters for VLCFA
into the peroxisomal matrix. It will be interesting
to determine if mammalian Pmp70 and ALDp,
when functionally expressed in yeast, are able to re-
store growth of vpxa1 cells on oleate, which would
further strengthen the use of yeast as model system
to study structure and function of the human ALD
peroxisomal disease genes.
2.5. The YEF3 and RLI subfamilies and unclassi¢ed
ORFs encoding ABC proteins
Two open reading frames, YFL028c and
YDR061w, have not been classi¢ed, as their sequen-
ces are more distantly related to typical ABC pro-
teins. Although they do contain at least one NBD
with degenerate ABC signature motifs, they lack pre-
dicted membrane-spanning regions. Likewise, no
TMSs are present in the RLI and YEF3 subfamilies,
with a total of seven members, two of which, Yef3p
[111] and Gcn20p [112], have been studied. While the
precise subcellular localization is as yet undeter-
mined, Yef3p appears to function as a translation
elongation factor [113] that could be associated
with the ribosome [114]. Notably, overexpression of
Yef3p renders cells hypersensitive to paromomycin
and hygromycin B, two translational inhibitors
[115]. YEF3 is the only essential yeast ABC gene,
since its deletion is lethal in vegetative yeast cells.
Interestingly, despite an 84% primary sequence iden-
tity, overexpression of a close Yef3p homologue,
Hef3p, cannot rescue loss of Yef3p. The Hef3p func-
tion remains unknown, but like Yef3p, it exhibits
ribosome-stimulated ATPase activity [116,117].
The role of the Gcn20p ABC protein is possibly in
the regulation of amino acid utilization. Gcn20p co-
immunoprecipitates with Gcn1p, indicating that
Gcn20p and Gcn1p are components of a protein
complex that couples a Gcn2p kinase activity to
the availability of exogenous amino acids. A deletion
of GCN20 in otherwise wild type strains impairs de-
repression of GCN4 translation and reduces the level
of eIF-2K phosphorylation in vivo, indicating that
Gcn20p is a positive e¡ector of Gcn2p kinase func-
tion [112]. A recent study suggests that the Gcn1p/
Gcn20p complex is a translational regulator of
Gcn4p, which functions on elongating ribosomes by
activation of the eIF2K kinase Gcn2p [118].
Other ABC proteins in this family have not been
studied so far, but they are very closely related to
either Yef3p or Gcn20p, implying a speculative role
in translation elongation, regulation of carbon source
utilization or amino acid starvation. Finally, the sin-
gle RLI family member YDR091c exhibits homology
to a human RNase L inhibitor, but its precise role in
yeast has not been determined [33].
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3. ABC proteins in the ¢ssion yeast
Schizosaccharomyces pombe
Several ABC proteins have also been discovered in
other fungal species including Schizosaccharomyces
pombe. Six ABC proteins, all of which are membrane
transporters, have been reported in ¢ssion yeast. The
protein encoded by the mam1 gene, a functional ho-
mologue of Ste6p, is responsible for the secretion of
the mating pheromone M-factor [119]. Three ABC
transporter genes were also isolated based on their
ability to confer multidrug resistance, i.e. pmd1 [120],
bfr1/hba2 [121,122], and the heavy metal tolerance
gene hmt1 [123]. The fourth member of the S. pombe
MDR subfamily, the Abc1p protein [124], still awaits
functional characterization. The mam1 gene is only
expressed in M-cells and its disruption leads to ster-
ility. The fact that ectopic expression of Ste6p could
restore mating ability in a mam1 mutant strain [119]
implies a functional conservation between these two
pheromone transporters. Whether Mam1p is capable
of exporting substrates other than M-factor remains
to be determined.
The ¢rst ¢ssion yeast gene conferring multidrug
resistance was pmd1 [120]. Overexpression of the P-
gp homologue Pmd1p confers resistance to the anti-
fungal drug leptomycin B, as well as various other
cytotoxic compounds. As expected, the null mutant
is hypersensitive to a number of drugs [120]. How-
ever, despite its homology to Ste6p, pmd1 mutants
do not show decreased mating abilities [125]. Inter-
estingly, actinomycin D hypersensitivity of a pmd1
null strain can be rescued by functional expression
of human P-gp, although human P-gp seems improp-
erly glycosylated in S. pombe [56].
While the S. cerevisiae half-size transporter Atm1p
exerts its function in the inner mitochondrial mem-
brane [43,44], the S. pombe homologue Hmt1p is
involved in the vacuolar sequestration of heavy met-
als [123,126]. Like plants and some other fungi, S.
pombe synthesizes phytochelatins, which act as che-
lators in heavy metal detoxi¢cation [127]. Interest-
ingly, the vacuolar membrane protein Hmt1p medi-
ates ATP-dependent transport of both apo-
phytochelatins and phytochelatin-Cd2 complexes
[126]. Since phytochelatins are synthesized from glu-
tathione, it is tempting to speculate that Hmt1p plays
a general role in the detoxi¢cation of GSH conju-
gates into the vacuole. It should be noted that the
vacuole represents the prime organelle for detoxi¢ca-
tion in plants. Like in yeast, several plant ABC trans-
porters have been identi¢ed, all of which are impli-
cated in vacuolar sequestration of poisonous
catabolites or environmental toxins [128^136].
It seems remarkable that the yeast PDR family,
the largest subfamily in baker’s yeast, has only one
homologue as yet in ¢ssion yeast. The non-essential
bfr1/hba2 gene was isolated through its ability to
confer brefeldin A resistance when overexpressed
[121,122]. Notably, Bfr1p/Hba2p shares with its
closest relatives, Pdr5p and Snq2p, a variation
from the N-terminal consensus Walker A motif
(GXXXXGK[S/T]), with the normally highly con-
served lysine replaced by a cysteine [121,122].
4. ABC proteins in pathogenic fungi and antifungal
resistance
It has been observed that long-term treatment of
fungal infections with triazoles can result in severe
antifungal resistance [137,138]. The discovery that
Pdr5p mediates pronounced resistance to mycotoxins
[61] and antifungal azoles [139] prompted the hunt
for Pdr5p homologues in pathogenic fungi. The gene
hunt was simpli¢ed by the fact that vpdr5 mutants
are hypersensitive to azole antifungals. Indeed, func-
tional restoration of miconazole [140] or £uconazole/
ketoconazole [139] resistance in vpdr5 mutants al-
lowed the identi¢cation of Cdr1p [139,140] and sub-
sequently Cdr2p [141] from the opportunistic patho-
gen Candida albicans. Further studies on clinical
strains revealed that there is a strong correlation be-
tween azole resistance and induced overexpression of
Cdr1p and Cdr2p [139,142]. For instance, the azole
minimal inhibitory concentration values of clinical C.
albicans isolates increase dramatically during re-
peated antifungal treatment. In fact, clinical isolates
exhibiting azole resistance frequently overexpress
ABC transporters such as Cdr1p and Cdr2p [25],
which share more than 60% primary sequence iden-
tity. Furthermore, deletion of both genes renders C.
albicans strains highly susceptible to azole antifun-
gals and many other drugs [143]. Surprisingly, a
lack of Cdr2p did not lead to a signi¢cant hyper-
susceptibility to Cdr1p substrates, most likely be-
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cause of the low Cdr2p expression, and because
Cdr1p alone mediates e⁄cient antifungal e¥ux.
However, deletion of Cdr2p in a vcdr1 background
aggravated growth inhibition by various antifungals
when compared to the single vcdr1 deletion mutant
[141]. Further, CDR2 mRNA levels are elevated in
clinical Candida isolates, suggesting that Cdr2p does
play a role in antifungal resistance [141]. As previ-
ously reported for Pdr5p and Snq2p [67,73,144], ex-
pression of Cdr1p in a drug-hypersensitive S. cerevi-
siae strain mediates e¥ux of L-estradiol and
corticosterone [145]. This transport process is en-
ergy-dependent and is inhibited to di¡erent extents
by other Cdr1p substrates [145]. A recent report also
suggested that Cdr1p acts as £ippase for phospha-
tidylethanolamine [146], a hypothesis that was earlier
proposed for mammalian P-gps [147] and yeast
Pdr5p [148]. Consistent with a function in membrane
lipid transport, changes in membrane £uidity also
appear to a¡ect Cdr1p function [149]. Like Cdr1p,
mammalian P-gps such as Mdr1 and Mdr2 act as
lipid £ippases with distinct phospholipid speci¢city
[150].
Taken together, active ABC pump e¥ux systems
are a prime cause of antifungal resistance, although
other resistance mechanisms such as changing mem-
brane permeability, target alteration, and facilitated
di¡usion also contribute to clinical resistance
[25,151]. Furthermore, ABC transporters implicated
in antifungal resistance in other fungal pathogens
have been identi¢ed. For instance, Pdh1p from Can-
dida glabrata is the closest homologue of yeast Pdr5p
with more than 72% primary sequence identity [152].
PDH1 mRNA levels are upregulated in azole-resis-
tant strains, although it cannot be excluded that
other £uconazole resistance genes might also be in-
duced [152]. Candida dubliniensis, another close rela-
tive of C. albicans, has also been reported to carry
ABC drug transporters implicated in £uconazole
resistance. The existence of Cdr1p and Cdr2p homo-
logues in C. dubliniensis has been demonstrated by
PCR [153]. Like the C. albicans CDR genes
[139,141,154^156], several clinical isolates showed in-
creased mRNA levels of CdCDR1. Finally, C. albi-
cans has two additional ABC genes whose products
do not appear to be involved in clinical azole resis-
tance, despite their homology to the drug e¥ux
pumps. Cdr3p seems to be an opaque-phase-speci¢c
transporter [157] of unknown function, and likewise
no function is known for Cdr4p [158].
The only Candida homologue of the baker’s yeast
MDR subfamily is HST6 [159], a functional homo-
logue of Ste6p. HST6 was isolated through its ability
to suppress the mating defect of a vste6 mutant, thus
mediating a-factor secretion. However, it is not clear
what the physiological function or substrate of Hst6p
might be, since C. albicans is a diploid, asexually
reproducing fungus that is not known to secrete mat-
ing pheromones. Notably, HST6 expression is re-
pressed in diploid S. cerevisiae cells, while it is con-
stitutively expressed in di¡erent cell types of C.
albicans [159]. In a recent study, a putative Yor1p
homologue from C. albicans was identi¢ed although
functional data were not presented [99]. Finally, the
Yef3p orthologue of the yeast Yef3p translation
elongation factor (see Section 2.5) has also been
identi¢ed in C. albicans [160].
The search for resistance transporters in other fun-
gal pathogens (Table 2) has led to the discovery of
ABC proteins in Aspergillus nidulans (AtrC [161],
AtrA and AtrB [162]), Aspergillus £avus and Asper-
gillus fumigatus (A£MDR1, AfuMDR1 and
AfuMDR2, respectively [163]), in Penicillium digita-
tum (Pmr1p [164]) and in Cryptococcus neoformans
(CneMDR1 and CneMDR2 [165]). Although few
functional data are available on these fungal ABC
transporters, their involvement in resistance develop-
ment was proposed because of their high homology
to yeast Pdr5p, Cdr1p and mammalian multidrug
resistance genes. A very interesting novel ABC trans-
porter was discovered in the plant fungus Magna-
porthe grisea, a phytopathogen causing rice blast dis-
ease. Remarkably, deletion of ABC1, a close
homologue of Pdr5p, in M. grisea causes a loss of
virulence, indicating that Abc1p is an important
pathogenicity factor [166]. Although the mechanism
is unclear, it seems plausible that Abc1p mediates
secretion of factors required for the invasion of plant
cells or that abc1 mutants are unable to detoxify
toxic plant metabolites that counteract infection
[166].
Finally, the regulatory mechanisms of CDR gene
expression are largely unknown. However, such
knowledge could be a key to the understanding of
PDR gene function and help to combat antifungal
resistance. By contrast, a large number of studies in
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baker’s yeast have unraveled a complex regulatory
network that controls PDR development. Hence,
the next section will be devoted to a discussion of
the yeast PDR network that regulates ABC gene ex-
pression under normal and adverse conditions.
5. Regulation of ABC gene expression ^ the yeast
PDR network
As discussed above, PDR can arise from overex-
pression of ABC drug e¥ux pumps. In addition,
mutations in genes encoding transcriptional regula-
tors also lead to a complex PDR phenotype. The
original discovery comes from observations showing
that the PDR5 gene is regulated by Pdr1p [167], and
that pdr5 mutants are hypersensitive to cyclohex-
imide [168]. Two transcriptional regulators, Pdr1p
[169] and Pdr3p [170,171], were identi¢ed, either
one of which can mediate PDR. While vpdr1 mu-
tants are hypersensitive to many drugs [71,167],
drug-resistant pdr1 mutants, so-called gain-of-func-
Table 2
ABC proteins identi¢ed in other fungi and fungal pathogens
ABC protein Substrate(s) Length Topology Localization Phenotype Reference
Candida albicans
Hst6p ? 1323 (TMS6-ABC)2 ? ? [159]
Cdr1p Antifungals 1501 (ABC-TMS6)2 PM DrugHS [139,140,142]
Cdr2p Antifungals 1499 (ABC-TMS6)2 ? DrugHS [143]
Cdr3p ? 1501 (ABC-TMS6)2 ? Viable [157]
Cdr4p ? 1490 (ABC-TMS6)2 ? Viable [158]
Elf1p ? 1191 ABC2 ? Slow-growth [207]
CaEf3p ? 1050 ABC2 ? ? [160]
Candida glabrata
Pdh1p Drugs 1542 (ABC-TMS6)2 ? ? [152]
Schizosaccharomyces pombe
Hba2p Brefeldin A 1530 (ABC-TMS6)2 ? DrugHS [121,122]
Abc1p ? 1427 (TMS6-ABC)2 ? Viable [124]
Pmd1p Drugs 1362 (TMS6-ABC)2 ? DrugHS [120]
Mam1p M-factor 1336 (TMS6-ABC)2 ? Sterile [119]
Hmt1p Phytochel./Cd2 830 TMS6-ABC Vac CdHS [123]
Aspergillus £avus
A£Mdr1p ? 1307 (TMS6-ABC)2 ? ? [163]
Aspergillus fumigatus
AfuMdr1p Drugs? 1349 (TMS6-ABC)2 ? ? [163]
AfuMdr2p ? 791 TMS4-ABC ? ? [163]
Aspergillus nidulans
AtrAp ? 1466 (ABC-TMS6)2 ? ? [162]
AtrBp Drugs? 1426 (ABC-TMS6)2 ? ? [162]
AtrCp ? 1293 (TMS6-ABC)2 ? ? [161]
Cryptococcus neoformans
CneMdr1p ? 1408 (TMS6-ABC)2 ? ? [165]
Magnaporthe grisea
Abc1p ? 1619 (ABC-TMS6)2 ? Reduced
pathogenicity
[166]
HS, hypersensitivity; Phytochel., phytochelatins; PM, plasma membrane; TMS, transmembrane segment; Vac, vacuole.
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tion mutants, overexpress not only Pdr5p [167] but
also Snq2p [71,72]. Numerous gain-of-function al-
leles of PDR1 [172] and PDR3 [173] were identi¢ed,
some of which cause various drug resistance pheno-
types [66,71,167,174], while others also increase
transmembrane £ipping of phospholipid analogues
[148]. However, it is not fully understood how point
mutations in PDR1 and PDR3 can cause such di-
verse phenotypes, except that they must act through
unknown target genes. Notably, neither the expres-
sion level nor the localization of the Pdr1p/Pdr3p
regulators is in£uenced by these mutations (Pandjai-
tan et al., in preparation). Thus, it is tempting to
speculate that an interaction with other as yet un-
identi¢ed transcriptional regulators and the subse-
quent modulation of target genes cause the pheno-
type variety.
5.1. The master regulators ^ Pdr1p and Pdr3p
Pdr1p and Pdr3p are closely related and belong to
the bi-nuclear Gal4p-like Zn(II)2Cys6 transcription
factors, which share a similar domain organization.
Deletion of both genes aggravates drug hypersensi-
tivity, suggesting that they have overlapping func-
tions [170]. The bi-nuclear Zn cluster at the N-termi-
nus mediates DNA binding. In their middle region,
several motifs are thought to be inhibitory domains,
while the C-terminal region harbors an acid-rich ac-
tivation domain (ARD) [172,173]. Furthermore, the
ARD seems to be the site for phosphorylation of
Pdr3p, since Pdr3p deletion mutants lacking the
ARD are no longer phosphorylated (Pandjaitan et
al., unpublished results). The functional importance
of Pdr1p/Pdr3p phosphorylation is unclear, since the
truncated non-phosphorylated form of Pdr3p is at
least partially functional (Mahe¤ et al., unpublished
results). Most gain-of-function mutations in PDR3
map to the ¢rst two motifs in the inhibitory domain,
where they most likely impair inhibition, and to the
ARD, where hyperactivation might be induced
[170]. In contrast, pdr1 mutations are scattered
throughout the entire protein with some hot spots
at the C-terminus [172]. Neither Pdr1p nor Pdr3p is
subject to a reversible cytoplasmic-nuclear shuttling,
as they constitutively localize to the nucleus (Pandjai-
tan et al., in preparation). However, the nuclear
localization or the function of at least Pdr1p seems
to require Pdr13p, a cytoplasmic Hsp70 homologue
[175].
Pdr1p and Pdr3p act through cis-acting sites
present in the promoters of target genes (Fig. 3).
The consensus motif was named PDRE (for pleio-
tropic drug resistance element) and later identi¢ed as
the perfect palindrome 5P-TCCGCGGA-3P [176,177].
Notably, a Pdr3p-mediated autoregulation of the
PDR3 gene carrying two perfect PDREs exists
[177], but the signals that activate this autoregulatory
loop are not known at present. PDREs come in dif-
ferent £avors (Fig. 2) which nevertheless retain their
ability to serve as Pdr1p/Pdr3p target sites. Hence,
limited variations in the consensus PDRE still enter-
tain Pdr1p/Pdr3p-mediated regulation (Fig. 2). Fur-
ther, promoter PDREs are present in di¡erent num-
bers ranging from one to four as well as in di¡erent
combinations. Whether or not this is important for
Pdr1p/Pdr3p regulation is not clear. While in vivo
studies are not available yet, in vitro studies using
recombinant GST-Pdr3p and GST-Pdr1p indicate
that each regulator can bind both perfect and degen-
erate PDREs of target genes [71,97,178^180]. More
importantly, Pdr1p and Pdr3p can form homo- and
heterodimers in vivo, indicating that target gene spe-
ci¢city could be brought about by Pdr1p/Pdr3p com-
plexes recognizing distinct PDRE combinations,
thereby exerting distinct regulatory functions. (Pand-
jaitan et al., in preparation). This might help to
explain why PDR5 transcription is grossly impaired
in vpdr1 cells [71,176], while SNQ2 transcription is
only abolished in vpdr1vpdr3 mutants [71], and
YOR1 transcription is only slightly a¡ected even in
a vpdr1vpdr3 double mutant [97]. The single vpdr
mutants also exhibit striking e¡ects. For instance,
PDR5 transcription is dramatically reduced in a
vpdr1 strain, whereas the PDR15 mRNA, the closest
homologue of PDR5, is increased [178]. The reason
for this complementary regulation is not understood,
but it clearly indicates that Pdr1p and Pdr3p can
exert positive and negative e¡ects on PDR target
genes. The function of Pdr1p/Pdr3p is perhaps sub-
ject to regulation by other transcription factors. For
instance, Ngg1p, a general transcription factor re-
quired for Gal4p-mediated glucose repression
[181,182], might inhibit Pdr1p through a physical
interaction with the Pdr1p/Pdr3p complex [183].
The ¢rst identi¢ed target genes for Pdr1p and
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Pdr3p were PDR5 and SNQ2 (Fig. 3). Both Pdr5p
and Snq2p levels are increased by an order of mag-
nitude in pdr1^3 mutants, while their expression is
virtually abolished in vpdr1vpdr3 double mutants
[71]. Thus, Pdr5p and Snq2p nicely describe the basic
PDR network comprised by regulators and target
pumps, which execute resistance development.
PDR5 and SNQ2 have several PDREs in their pro-
moters (Fig. 2), and both are controlled by Pdr1p/
Pdr3p. However, PDR5 and SNQ2 are by no means
the only genes of the PDR family with promoter
PDREs. For instance, PDR10 and PDR15 transcrip-
tion is strongly a¡ected by Pdr1p and Pdr3p, show-
ing that both Pdr10p and Pdr15p are subject to reg-
ulation within the PDR network. Likewise, the
oligomycin transporter Yor1p is also regulated by
Pdr1p/Pdr3p through a single degenerate PDRE
[97]. Hence, at least one functional PDRE appears
necessary and su⁄cient to confer Pdr1p/Pdr3p regu-
lation [97,184].
Interestingly, two non-ABC genes with PDREs are
also known. The HXT9 and HXT11 genes encode
members of the large family of hexose transporters
[180]. Basal expression of both HXT9 and HXT11 is
indeed regulated by Pdr1p and Pdr3p, and Hxt9p/
Hxt11p overexpression leads to drug hypersensitivity
[180]. Although this is in contradiction to other
Pdr1p/Pdr3p targets whose overproduction leads to
drug resistance, it seems plausible that higher perme-
ase levels at the cell surface cause increased uptake of
toxic compounds, particularly since hexose trans-
porters are supposed to mediate uptake of molecules
rather than e¥ux. Finally, the PDR12 gene encoding
a weak acid pump also contains one degenerate
PDRE (Fig. 3). It might be that Pdr1p/Pdr3p exert
a basal regulatory e¡ect on PDR12, since the corre-
sponding mRNA levels are decreased in pdr1/pdr3
mutants (Pandjaitan et al., unpublished data). How-
ever, this PDRE does not contribute to PDR12 reg-
ulation under stress [78].
5.2. Stress and ABC transporters ^ the Yap family
The second family of transcription factors regulat-
ing ABC protein expression is the bZip protein fam-
ily, also known as the Yap family. They are related
to the mammalian AP-1 transcription factor, a het-
erodimer of c-jun and c-fos, and to yeast Gcn4p.
Eight related family members exist in yeast, and at
least three of them are implicated in drug resistance
Fig. 3. The PDR network. The genes in the center represent
ABC transporters and/or Pdr1p/Pdr3p target genes, which are
currently known to be regulated by the transcriptional regula-
tors above (Pdr1p/Pdr3p) and below (Yap1p, Yrr1p, Yap2p,
Msn2p/Msn4p).
Fig. 2. Di¡erent PDREs are present in the promoter regions of
Pdr1p/Pdr3p target genes. The underlined residues represent de-
viations from the perfect palindromic PDRE 5P-TCCGCGGA-
3P.
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through the regulation of ABC transporters [185].
The best characterized member of this family is
YAP1/PAR1/SNQ3/PDR4 [186^188], whose function
in stress response is also well documented [174,187^
189]. Gene activation by Yap1p is mediated through
ARE (AP-1 response element; 5P-TTAG/CTAA-3P)
and the motif mediating Gcn4p binding, both of
which are also recognized by other members of the
Yap family [93,187,190].
Since YAP1 overexpression causes Cd2 resistance,
a possible regulation of Ycf1p was investigated. In-
deed, YAP1-mediated Cd2 resistance requires func-
tional Ycf1p. However, hyperresistance to Cd2 as a
consequence of YCF1 overexpression is only partially
dependent on the presence of functional Yap1p [94].
This hints at the existence of one or more additional
regulators mediating stress response through YCF1
regulation. Indeed, overexpression of Yap2p, a bZip
protein with homology to Yap1p, mediates Cd2 re-
sistance only in the presence of Ycf1p [187]. Yap2p
has also been identi¢ed as the CAD1 gene in a ge-
netic screen for cadmium resistance [187]. While
vcad1 deletion strains show elevated Cd2 sensitivity,
Cad1p overexpression causes resistance. Moreover,
vyap2 strains are also hypersensitive to oxidative
stress [191]. Although Yap1p is much more impor-
tant for oxidative stress response, Yap2p is clearly
involved as well. Notably, a strain lacking Yap8p
(Acr1p), another Yap member, is sensitive to arsenite
and arsenate. However, the Yap8p target gene has
not been identi¢ed, but the Ycf1p-mediated arsenite
and arsenate resistance phenotype [92] implies a con-
nection between Yap8p and Ycf1p [192]. Consistent
with these ¢ndings, a functional YRE is present in
the YCF1 promoter [94].
Like Pdr1p and Pdr3p, Yap1p also contains an
ARD at its C-terminus. In contrast to Pdr1p/
Pdr3p, however, the Yap1p ARD confers negative
regulation, since a mutant Yap1p lacking the ARD
is constitutively active [95,193]. This activation is
most likely mediated through a constitutive nuclear
localization of mutant Yap1p. In unstressed cells,
Yap1p is di¡usely dispersed throughout the cyto-
plasm, but rapidly shuttled into the nucleus in re-
sponse to stress, requiring the Ran1p shuttle [194].
The regulation of Yap1p is not only con¢ned to its
localization, but might also occur at the transcrip-
tional level. Interestingly, both YAP2 and YAP1
have an upstream open reading frame in their 5P-
untranslated region, which negatively regulates both
YAP1 and YAP2, since its deletion causes elevated
transcription [195]. Yap1p also controls many other
stress response genes, including FLR1 [196], TPS2
[189], TRX2 [190], GLR1 [197] or GSH1 [198].
When activated by an oxidizing environment,
Yap1p induces target genes that are important for
maintaining cellular viability under stress. While
the role of ABC genes in this process is unknown,
it could be that ABC transporters are responsible for
extracellular or vacuolar detoxi¢cation of toxic com-
pounds produced under oxidative stress. The Ycf1p
function in vacuolar sequestration of GSH conju-
gates supports this idea.
In addition to Pdr1p/Pdr3p and Yap1p, there is at
least one additional regulator of the Zn(II)2Cys6
family, Yrr1p [199], involved in ABC transporter
regulation. Control of Snq2p expression in response
to stress requires Yrr1p, particularly for the 4-NQO-
mediated induction of SNQ2 mRNA levels. Further-
more, a yrr1 gain-of-function mutation also induces
YOR1 mRNA levels [199], con¢rming that Yor1p is
part of the PDR network. Moreover, expression of
SNQ2 in response to stress is also regulated by
Yap1p, since induction of Snq2p biosynthesis re-
quires Yap1p (Mahe¤ et al., in preparation). However,
there is no obvious YRE in the SNQ2 promoter,
indicating that yet unknown elements might mediate
Yap1p regulation of SNQ2. Alternatively, Yap1p
could act through Pdr1p or Pdr3p without directly
binding to the SNQ2 promoter region. Thus, regula-
tion of SNQ2 expression under normal and adverse
conditions involves at least four distinct regulators:
Pdr1p, Pdr3p, Yrr1p, and Yap1p [71,199]. Likewise,
diazaborine resistance development is dependent on
Pdr1p/Pdr3p and Yap1p [174], although in this case
the actual target gene and mechanism is unknown.
The fact that Yap1p-mediated diazaborine resistance
requires functional Pdr1p/Pdr3p, suggests a function-
al cross-talk between the PDR network and stress
response [174].
Finally, we have recently obtained evidence that
transcription factors of the high osmolarity glycerol
(HOG) pathway are involved in the regulation of the
Pdr15p ABC transporter (Wolfger et al., in prepara-
tion). In addition to PDREs, PDR15 contains several
STREs (stress response elements) in its promoter
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[178]. These motifs (5P-CCCCT-3P or 5P-AGGGG-3P)
mediate stress response through a heterodimeric
Msn2p/Msn4p transcription factor complex [200^
202]. STRE-mediated regulation is required for the
HOG signaling pathway, which comprises a two-
component osmo-sensing system, a mitogen-acti-
vated protein kinase cascade, and the downstream
e¡ectors Msn2p/Msn4p [80]. PDR15 mRNA and
protein levels are strongly induced in response to
several stresses, including heat shock and osmotic
stress (Wolfger et al., unpublished results). This in-
duction requires functional Msn2p but surprisingly is
independent of Hog1p and Pbs2p, the upstream reg-
ulatory kinases of the HOG pathway (Wolfger et al.,
in preparation). These data provide evidence for a
novel and as yet unidenti¢ed signaling cascade oper-
ating in parallel to the HOG pathway but converging
at the Msn2p/Msn4p downstream e¡ectors for
PDR15 stress induction (Wolfger et al., unpublished
results).
Still little is known about the regulation of drug
e¥ux pumps in pathogenic fungi. It should be men-
tioned that the 5P-untranslated region of the Candida
glabrata PDH1 ABC transporter contains a sequence
at position 3200 to 3190 that strongly resembles the
yeast PDRE [152]. While the Pdr1p/Pdr3p homo-
logues from C. albicans have been identi¢ed recently
[203], it is not known if similar proteins exist in C.
glabrata which would recognize these PDRE-like el-
ements. Another indication for a functional cross-
talk between drug resistance and stress response in
pathogens comes from the identi¢cation of Cap1p
[204], a homologue of Yap1p. Cap1p appears to be
implicated in antifungal resistance as well as stress
response in C. albicans [204].
To come to full circle, the complex connections
within the yeast PDR network are depicted in Fig.
3. It seems reasonable to predict that the transcrip-
tional regulators and target genes known to date
comprise only a part of the whole regulatory net-
work involved in the regulation of ABC transporters
under physiological and adverse conditions. There is
already evidence for novel regulators of ABC trans-
porters such as the weak acid pump Pdr12p, since its
induced expression under stress is independent of
Pdr1p/Pdr3p, Yap1p, and Msn2p/Msn4p [78]. In ad-
dition, the case example of PDR15 indicates that
parallel stress signaling cascades may converge at
downstream e¡ectors such as Msn2p/Msn4p. The ex-
isting connections between PDR regulation and
stress suggest physiological functions of ABC trans-
porters in stress response, promising a tremendous
experimental challenge for the years to come.
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